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1  | INTRODUC TION
Adequate amino acid (AA) supply is vital especially for highly prolif-
erative tissues like the placenta. Other tissues which are critical for 
nutrient absorption and transport, such as the intestine and liver, 
mainly use the efficient sodium (Na+)-dependent uptake maintained 
by System A transporters,1 such as the SNAT family.2 The hetero-
meric SLC7 AA transporters, a subgroup of the System L-exchanger 
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Abstract
The placenta supplies the foetus with critical nutrients such as essential amino acids 
(AA, eg leucine) for development and growth. It also represents a cellular barrier 
which is formed by a polarized, differentiated syncytiotrophoblast (STB) monolayer. 
Active Na+-independent leucine transport across the placenta is mainly attributed 
to the System L transporters LAT1/SLC7A5 and LAT2/SLC7A8. This study ex-
plored the influence of trophoblast differentiation on the activity of LAT1/LAT2 
and the relevance of LAT1/LAT2 in leucine uptake and transfer in trophoblasts by 
applying specific small molecule inhibitors (JPH203/JG336/JX009). L-leucine up-
take (total dose = 167 μmol/L) was sensitive to LAT1-specific inhibition by JPH203 
(EC50 = 2.55 µmol/L). The inhibition efficiency of JPH203 was increased by an 
additional methoxy group in the JPH203-derivate JG336 (EC50 = 1.99 µmol/L). 
Interestingly, JX009 showed efficient System L inhibition (EC50 = 2.35 µmol/L) and 
was the most potent inhibitor of leucine uptake in trophoblasts. The application of 
JPH203 and JX009 in Transwell®-based leucine transfer revealed LAT1 as the major 
accumulative transporter at the apical membrane, but other System L transporters 
such as LAT2 as rate-limiting for leucine efflux across the basal membrane. Therefore, 
differential specificity of the applied inhibitors allowed for estimation of the contri-
bution of LAT1 and LAT2 in materno-foetal AA transfer and their potential impact in 
pregnancy diseases associated with impaired foetal growth.
K E Y W O R D S
BeWo, LAT1 (SLC7A5), LAT2 (SLC7A8), leucine uptake, monolayer, placenta, transplacental 
amino acid transport, Transwell, trophoblast, trophoblast differentiation
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2  |     ZAUGG et Al.
family, are driven by System A-dependent AA gradients. Both AA 
transporter families are highly expressed in polarized epithelial tis-
sues such as blood-brain and placental barriers.3,4 There are two 
important cell layers in the placental villi coordinating the nutrient 
transfer across the placental barrier, namely syncytiotrophoblasts 
(STB) and foetal capillary endothelial cells. Endothelial cells lining 
the foetal vessels allow relatively unrestricted paracellular diffusion 
of small molecules like glucose and AA through endothelial junc-
tions.5 In contrast, STB represent the limiting barrier for AA due to 
the formation of an epithelial syncytium composed of two polarized 
monolayers, the microvillous plasma membrane (MVM) facing the 
maternal blood supply and the basal membrane (BM) directed to-
wards the foetal capillary (Figure 1A).
The Na+-independent System L transporters expressed in the 
human placenta are heterodimeric exchangers consisting of the 
light chain L-type AA transporter LAT1 (SLC7A5) or LAT2 (SLC7A8) 
covalently attached to the heavy chain 4F2hc (SLC3A2). Moreover, 
the SLC43 family members LAT3 (SLC43A1) and LAT4 (SLC43A2), 
known to be involved in facilitated AA diffusion,6,7 are expressed 
at the BM (Figure 1A). Both LAT1 and LAT2 are predominantly lo-
calized to the MVM of human term placenta, LAT2 as well as LAT3 
and LAT4 are also present at the BM and in endothelial cells lining 
the foetal capillaries.7,8 In the last decade, increasing evidence sug-
gests a tight link between the reduced activity of placental System 
L transporters and intrauterine growth restriction (IUGR),9,10 and 
their up-regulation in placentae of large for gestational age (LGA) 
infants.11 Such altered foetal development has a fundamental impact 
on lifelong health and wellbeing, and may contribute by foetal pro-
gramming to an increased prevalence for cardiovascular disease and 
diabetes/adiposity later in life.12-15 Notably, it has been reported that 
LAT1 or its associated glycoprotein 4F2hc is involved in placenta de-
cidualization and fusogenic trophoblast differentiation.16 This could 
imply that the diminished leucine uptake found in knock-down cell 
models17 results rather from failure in trophoblast differentiation 
than from reduced SLC7 transport activity. Hence, small molecules 
which induce only short-term inhibition of transporter activity are a 
valuable experimental tool to study placental transfer mechanisms 
as they will not affect trophoblast differentiation and associated 
processes like trophoblast fusion. Therefore, studying placental AA 
transfer by using specific small molecule inhibitors of AA transport-
ers instead of silencing or knock-out could help to reveal the rele-
vance of LAT1 or LAT2 in materno-foetal leucine transfer without 
affecting cell differentiation.
Since LAT1 was found to be selectively expressed and up-regu-
lated in various rapidly proliferative cancer types18-20 and has a pu-
tative role in drug delivery across the blood-brain barrier,21 efforts 
have been made to pharmaceutically target this transporter using 
substrate-mimicking or virtual screening approaches.22-26 The sub-
strate-mimicking tyrosine analog JPH203 (also known as KYT-0353) 
was tested in several in vitro and in vivo cancer cell proliferation 
experiments and described as potent LAT1-specific inhibitor.27-31 
To delineate the contribution of LAT1 from LAT2 in materno-foe-
tal leucine transport, we synthesized the LAT1-specific inhibitor 
JPH203, the structurally closely related inhibitor (JG336), as well as 
a third small molecule inhibitor (JX009) with comparable leucine up-
take inhibition efficiency but lower LAT1-specificity (structures see 
Figure 4).
In this study, we assessed the contribution of LAT1-mediated 
Na+-independent leucine uptake into trophoblasts and investigated 
the transfer of this essential AA across the placental barrier by tran-
sient inhibition. To achieve these goals, we (a) tested primary human 
trophoblast and BeWo (clone b30) cell models for LAT1, LAT2 and 
4F2hc expression and leucine uptake capacity under Na+-free con-
ditions, (b) investigated whether the differentiation status of primary 
trophoblasts and BeWo cells has an impact on leucine uptake and 
(c) assessed the contribution of LAT1 for the uptake and transfer of 
leucine by application of small molecule inhibitors.
2  | MATERIAL S AND METHODS
All chemicals and reagents were purchased from Sigma-Aldrich in 
Switzerland unless otherwise stated.
2.1 | Isolation of primary human trophoblast cells
Placentae from normal healthy pregnancies were collected after 
elective Caesarean section at the Division of Gynecology and 
Obstetrics, Lindenhofgruppe, Bern, Switzerland. Details on the 
study subjects are found in Table 1. The study was conducted in 
accordance with the Declaration of Helsinki, and the protocol was 
approved by the Ethics Committee of the Canton of Bern (Basec 
Nr2016-00250). The collected tissue was used to isolate primary 
cytotrophoblasts as previously described.32 Isolated cells were cul-
tured on Cell-BIND plates in Dulbecco's modified Eagle's medium 
containing 4.5 g/L glucose (DMEM-highGlucose; Gibco, Paisley, 
UK) and characterized by analysing the expression of cytokeratin-7 
and vimentin as previously described.33 Primary trophoblasts were 
evaluated for leucine uptake at the cytotrophoblast (CTB) and syn-
cytiotrophoblast (STB) stage (ie after 12 and 48 hours of culture, 
respectively) when spontaneous differentiation and fusion has 
occurred.
2.2 | BeWo cell culture
BeWo cells (clone b30) were cultured in DMEM containing 1.0 g/L 
glucose (DMEM-lowGlucose; Gibco). BeWo cells require stimula-
tion by forskolin to induce STB formation.34 Unstimulated BeWo 
cells representing the CTB stage were studied after 24 hours of cul-
ture; differentiated, syncytialized BeWo cells were analysed after 
stimulation with 100 μmol/L forskolin for 48 hours when markers 
for syncytialization are significantly increased.32 For leucine trans-
fer experiments, BeWo cells were seeded at a density of 100 000 
cells/cm2 onto permeable membranes (0.4 μm pore size) mounted in 
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12-well format from the Transwell® system (Corning Inc., Corning, 
NY, USA). Cells were cultured in DMEM-lowGlucose at 37°C with 
5% CO2 atmosphere for 7-14 days.
2.3 | Placental membrane protein isolation
Placental tissues from healthy pregnancies were used to simultane-
ously isolate microvillous membranes (MVM) and basal membranes 
(BM) by Mg2+ precipitation based on a published method35 and de-
scribed in the Supporting Information. Expression levels in MVM and 
BM were normalized to the total membrane isolation (TMI) fraction 
collected prior to Mg2+ precipitation for MVM/BM separation. Further 
details regarding the enrichment and characterization of the MVM/BM 
fractions are found in Supporting Information and Figure S1.
2.4 | LAT1 localization by 
immunohistochemistry and immunoblotting
LAT1 protein was localized in two experimental approaches. LAT1 
expression in MVM and BM fractions was determined by immu-
noblotting using rabbit polyclonal anti-LAT1 antibody (Anti-human 
LAT1, KE026/TG170215 Transgenic Inc., Kobe, Japan; 1:1000). 
F I G U R E  1   Schematic representation of Na+-independent leucine transfer across the placental barrier with asymmetric LAT1 expression. 
Scheme of the placental villous structures as interface between the foetal capillaries and the maternal circulation (A, upper left panel) 
and the human placental barrier (A, upper right panel) involving three different cell types: endothelial cells lining the foetal capillaries 
(EC), varying intercellular space (pink), single-nucleated cytotrophoblasts (CTB) and syncytiotrophoblasts (STB) forming a multi-nucleated 
monolayer, which is in direct contact with maternal blood and mainly responsible for materno-foetal nutrient transport. In (A) lower panel, 
Na+-independent System L exchanger and System L-like facilitators known to be expressed in the human placenta are shown. They are 
present either at the apical microvillous membrane (MVM) or at the basal membrane (BM) of STB. LAT1 (SLC7A5), expressed at the MVM, 
and LAT2 (SLC7A8), present at both the MVM and BM, are SLC7 family members and colocalize with their heavy chain partner 4F2hc 
(SLC3A2, CD98). LAT3 (SLC43A1) and LAT4 (SLC43A2) were described as System L-like facilitators and are most likely expressed at the BM. 
Increased intracellular leucine concentrations stimulate mTORC1-mediated cell proliferation and survival, and repress the ATF4-mediated 
amino acid balance sensing system, which reduces global translation and increases biosynthesis. (B) Representative picture showing apical 
LAT1 localization in immunohistochemistry of human term placenta. Arrows indicate the apical MVM, that is, maternal blood orientated 
side; arrowheads depict the BM of the STB. There was no signal in negative control. (C) upper panel, representative immunoblot of 6 purified 
membrane protein samples isolated from term placental tissues. (C) lower panel, LAT1 was highly expressed in MVM, but negligible in BM 
protein fractions isolated from a total of 11 human term placentae. The data is normalized to the respective tissue homogenate before 
membrane separation and shown as boxplots with Tukey whiskers (Mann-Whitney test, α = 0.05; ***P < 0.0001)
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For the reference signal (loading control) a mouse anti-beta-actin 
antibody (A2228, Sigma Aldrich, Buchs SG, Switzerland) was used. 
Details regarding the immunoblotting procedures are described 
in Supporting Information. Densitometrical analysis of immunob-
lots was performed using the LI-COR OdysseyW Imaging System. 
LAT1 expression in placental tissue was visualized by immunohis-
tochemistry using the same LAT1-specific antibody (10 µg/mL). The 
preparation of cryosections and the staining procedure including 
visualization are described in Supporting Information.
2.5 | Expression changes of LAT1, LAT2 and 4F2hc 
during trophoblast differentiation
To compare changes in expression of LAT1, LAT2 and 4F2hc dur-
ing cell differentiation, mRNA and protein levels were determined 
by RT-qPCR and immunoblotting, respectively. RNA isolation, first-
strand cDNA synthesis and RT-qPCR analysis were performed as 
previously described.36 Expression results were normalized to the 
mean of the reference genes YWHAZ, GAPDH and β-actin. Primer 
nucleotide sequences are listed in Table S1. For protein quantifi-
cation 40 µg cell lysates were loaded on 10% acrylamide gels and 
separated by SDS–PAGE. The immobilized bands were semi-dry 
transferred to nitrocellulose membranes (GE Healthcare, Glattbrugg, 
Switzerland). Blots were blocked with 5% w/v non-fat milk in Tris 
Buffered Saline with 0.1% Tween-20 (TBST). Proteins were de-
tected by antibodies against LAT1 (see above), LAT2 (Anti-SLC7A8, 
AV43930, Sigma-Aldrich) and 4F2hc (CD98 (E-5), sc-376815, Santa 
Cruz, Biotechnology Inc., Heidelberg, Germany). Protein content 
was measured using a commercial Pierce™ BCA Protein Assay Kit.
2.6 | Leucine uptake assay
The leucine uptake protocol was based on a recently published 
method30 and adapted to physiological leucine concentrations. In 
brief, BeWo cells were seeded at a density of 60 000 cells/well into 
white-walled 96-well plates (Corning). The isolated primary tropho-
blasts were seeded at a density of 100 000 cells/well on 96-well plates 
which were coated with Matrigel (BD, New Jersey, USA) according 
to the suppliers' instructions. Primary trophoblasts and BeWo cells 
were cultured until they reached their assigned differentiation 
stage and then washed 3-times with pre-warmed Na+-free Hank's 
buffer (125 mmol/L choline chloride, 25 mmol/L HEPES, 4.8 mmol/L 
KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 1.3 mmol/L CaCl2, 
5.6 mmol/L glucose, adjusted pH to 7.4). After equilibration in the 
same buffer (37°C, 7 minutes), cells were incubated for 3 minutes 
with pre-warmed Na+-free Hank's buffer containing 167 μmol/L 
L-leucine and 20 nmol/L radioactive L-[3,4,5-3H(N)]-leucine 
(PerkinElmer, Waltham, MA, USA). Leucine uptake was stopped by 
three washing steps with ice-cold Na+-free Hank's buffer. The use 
of Na+-free buffer prevents leucine uptake by other Na+-dependent 
transporters such as System A-family members. Cells were lysed by 
intense shaking for 1.5 hours in MicroScint™-20 scintillation liquid 
(PerkinElmer). 3[H]-leucine was quantified using TopCount® NXT™ 
Scintillation and Luminescence Counter (PerkinElmer).
2.7 | Specific inhibition of LAT1/2 mediated 
placental leucine uptake
JPH203, JG336 and JX009 were synthesized following the routes 
described in the European Patent Application EP 2-959-918-A1, 
2014. Compounds were obtained as hydrochlorides, dissolved in di-
methyl sulfoxide (DMSO, Merck, Darmstadt, Germany) and applied 
in the concentration range from 0.001 to 31.6 μmol/L. JPH203 has 
been characterized as highly LAT1-specific; JX009 is described as 
LAT1 and LAT2-specific inhibitor.37 JG336 is a derivate of JPH203 
with an additional methoxy group at the peripheral phenyl moi-
ety residue. Compound structures are depicted in Figure 4. The 
1H-NNMR and 13C-NMR spectra data of the compounds were in 
agreement with the expected structures and are included in the 
Supporting Information.
2.8 | Leucine transfer across a polarized 
trophoblast monolayer
Before starting the transfer experiment, the formation of a tight troph-
oblast monolayer in BeWo cells was monitored by measuring tran-
sepithelial electrical resistance (TEER, [Ω*cm2]) and passive diffusion 
as reported previously.38 TEER and cellular capacitance (Ccl, [µF/cm
2]) 
were measured every 30 minutes and analysed using the cellZscope 
system (nanoAnalytics, Münster, Germany) according to the manu-
facturer's instructions. The apparent permeability coefficient (Papp, 
[cm/s]) was calculated by measuring the rates of passive transfer of 
the paracellular pathway marker Lucifer yellow (LY) as previously de-
scribed.39 BeWo monolayers with verified tightness were selected 
after 7 days of culturing on Transwell® membranes and randomly as-
signed to leucine transfer time courses and inhibition experiments. 
The inserts with cultured BeWo cells and an insert without cells (no 
cell control) were placed in 12-well plates and washed 3-times with 
pre-warmed Na+-free Hank's buffer. Prior to starting the time course, 
TA B L E  1   Anthropometric characteristics of healthy patients 
donating placental tissue and their offspring
Characteristics
Healthy 
controls
Mother Number of individuals 11
Maternal age (y) 33.9 ± 3.48
Parity 1.8 ± 0.60
Gestational age at partum 39 3/7 ± 6/7
Newborn Weight of placenta (g) 569.3 ± 86.1
Weight of baby (g) 3367.3 ± 284.0
Sex of baby 3♂/6♀
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the cells were equilibrated in Hank's buffer for 30 minutes at 37°C. 
Leucine transfer from the upper (maternal) towards the lower (foetal) 
compartment was started by simultaneously replacing the buffer in 
both compartments. The buffer in the lower chamber was replaced 
with Na+-free Hank's containing 300 μmol/L glutamine and 167 μmol/L 
unlabelled L-leucine to obtain a physiological counter-directed leu-
cine gradient. Consecutively the buffer in the upper compartment 
was replaced with Hank's containing 30 μmol/L leucine (labelled with 
3.7 nmol/L L-[3,4,5-3H(N)]-leucine), 300 μmol/L glutamine and either 
vehicle (DMSO) or a constant 10 µmol/L-dose of JPH203, JG336 or 
JX009, respectively. Inhibitors were applied in the upper compartment 
which is comparable to previous in vivo experiments.40 At defined time 
points between 5 minutes and 6 hours, 50 µL samples were taken from 
the maternal and foetal compartment. At the end of the experiment, 
all membranes were washed twice with DPBS and sampled to deter-
mine intracellular leucine levels. The medium and membrane samples 
including no cell controls were collected in 3 mL of scintillation cocktail 
(Zinsser Analytic, Frankfurt, Germany). Radioactivity was quantified 
using Tri-carb 2100TR Liquid Scintillation Counter (PerkinElmer).
2.9 | Statistical analysis
Anthropometric and clinical data are expressed as mean ± standard 
deviation (SD) for normal distribution or median with interquartile 
range for not normal distribution. Student t tests were performed 
to detect differences in mRNA levels between CTBs and STBs. 
MVM and BM membrane protein fractions were compared by using 
Mann-Whitney test. A P-value <0.05 was considered as statistically 
significant. Statistical comparisons were performed using GraphPad 
Prism software, La Jolla, USA.
3  | RESULTS
3.1 | LAT1, LAT2 and 4F2hc are asymmetrically 
expressed in the human placenta
Histological investigation of healthy placental tissue demonstrated 
strong expression of LAT1 at the apical membrane of STB (arrows 
in Figure 1B) which was confirmed by the strong signal found in the 
MVM fraction (Figure 1C). The asymmetric expression of LAT1 in syn-
cytialized trophoblasts was further confirmed by immunoblot analysis 
in paired MVM/BM isolated from term control placentae. LAT1 was 
predominantly expressed at the MVM as reflected in a mean MVM to 
BM ratio of 6.9 (range 3.5-14.9; Figure 1C). Western blot analysis of 12 
MVM and BM pairs revealed a significantly higher expression of LAT1 
in MVM compared to BM (P = 0.0015; Figure 1C). The results of these 
two independent experimental approaches suggest almost exclusive 
LAT1 expression at the apical membrane which is in direct contact with 
maternal blood. In contrast, LAT2 was found to be expressed in both 
MVM and BM (Figure S2), with an apparent predominance of the two 
LAT2 variants (30 and 50 kDa) in BM as reported before.4 Expression 
of 4F2hc, the heavy chain partner protein of LAT1 and LAT2, was 
higher in MVM as compared to BM (Figure S2).
3.2 | Trophoblast differentiation induces up-
regulation of LAT1 and 4F2hc expression
To study the role of LAT1 at the placental barrier on the cellular level, 
LAT1 expression during trophoblast differentiation was analysed 
in both primary human trophoblast cells and in the BeWo cell line 
model on mRNA and protein level. Forskolin-stimulated differentia-
tion in BeWo cells resulted in a significant up-regulation of LAT1 and 
4F2hc, but no significant changes for LAT2 were observed (Figure 2A). 
Spontaneously occurring trophoblast differentiation in primary troph-
oblasts tended to increase LAT1 and 4F2hc mRNA levels, but due to 
the high variation between the individual placental cell isolations this 
effect did not reach statistical significance (Figure 2B). Interestingly, 
protein analysis by immunoblotting revealed a clear difference in the 
protein expression pattern between LAT1 and LAT2 depending on 
the differentiation state: while both 50 kDa and 30 kDa LAT2 vari-
ants were predominantly found in undifferentiated primary CTB and 
BeWo-CTB, LAT1 protein levels were clearly increased in differenti-
ated primary STB and BeWo-STB (Figure 2C). Furthermore, increased 
4F2hc expression was detected after differentiation in both primary 
and BeWo cells. 4F2hc protein expression was identified in the form 
of multiple bands ranging from 70 to 120 kDa under reducing condi-
tions. The expression pattern of 4F2hc was found previously and is 
presumably due to formation of 4F2hc/4F2hc homodimers, 4F2hc/
LAT2 heterodimers and 4F2hc monomers.16,41,42 BeWo cells exhibited 
higher expression levels, but comparable expression changes during 
differentiation as primary trophoblasts.
3.3 | Leucine uptake increases with trophoblast 
differentiation
We further investigated whether the expression changes caused by 
trophoblast differentiation resulted also in an increased leucine uptake 
efficiency in both primary (n = 3; Figure 3A) and BeWo cells (n = 3; 
Figure 3B). Indeed, both spontaneously differentiated primary tropho-
blasts (pCTB-Vmax = 1.05 nmol/mg protein vs pSTB-Vmax = 2.34 nmol/
mg protein = 2.2-fold) and forskolin-stimulated BeWo cells (BeWo-
CTB-Vmax = 4.96 nmol/mg protein vs BeWo-STB-Vmax = 13.41 nmol/
mg protein = 2.7-fold) reached more than 2-times higher maximal up-
take levels after 6 minutes compared to the undifferentiated stage. 
By comparing maximal leucine uptake levels between BeWo and pri-
mary cells, a 4.7-fold greater uptake capacity for the BeWo-CTB and 
5.7-fold difference for the BeWo-STB stage was observed. However, 
the half-maximal leucine uptake time, calculated as Kd from the time 
course curve fit, for primary cells (pCTB-Kd = 1.45 nmol/min; pSTB-
hillslope = 1.36 nmol/min) and BeWo cells (BeWo-CTB-Kd = 1.19 nmol/
min; BeWo-STB-Kd = 1.42 nmol/min) was similar between the differ-
entiation stages. Thus, in accordance to expressional changes, also 
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on functional level leucine uptake capacity was higher in BeWo cells 
compared to primary trophoblasts, but the kinetic changes due to cell 
differentiation were similar in both cell models (Figure 3).
3.4 | Leucine uptake is modulated by System 
L-specific small molecule inhibitors
Based on the high leucine uptake capacity and the high expression 
levels of functional LAT1, the BeWo cell model was selected to test 
different LAT1 or LAT1/LAT2-specific small molecular inhibitors 
in dose-response experiments. Two new alternative compounds, 
JX009 and JG336 (Figure 4B,C), were investigated and compared in 
two separate experiments to the already established potent LAT1-
specific inhibitor JPH203 (Figure 4A). In BeWo-CTB all three inhibi-
tors reached a maximal inhibition of less than 0.8 nmol/mg protein 
at a concentration of 10 µmol/L (corresponding to the bottom value 
of a four-parameter nonlinear fit with variable slope; kinetic param-
eters are listed in the panels on the right). The leucine analog 2-amino-
2-norbornane-carboxylic acid (BCH) maximally inhibited leucine 
uptake at a concentration of approx. 1 mmol/L regardless of the dif-
ferentiation stage (Figure 4D). This observation further verifies the 
relevance of SLC7-mediated leucine uptake in BeWo cells. Although 
there was profound leucine uptake inhibition in BeWo-CTB, 10 µmol/L 
of JPH203 and JG336 showed a residual uptake of 3.8 (56.3% inhibi-
tion) and 3.2 nmol/mg protein (62.4% inhibition), respectively. JX009 
F I G U R E  2   Expression patterns of the placental System L transporters in primary trophoblasts and BeWo cells depend on their 
differentiation stage. Comparison of the choriocarcinoma derived BeWo cell line (A) and primary trophoblasts (B) with respect to LAT1 
(SLC7A5), LAT2 (SLV7A8) and 4F2hc (SLC3A2, CD98) mRNA levels at the undifferentiated cytotrophoblast (CTB) and differentiated 
syncytiotrophoblast (STB) stage. (A) LAT1 and 4F2hc were up-regulated, while LAT2 expression in BeWo-STB cells was not significantly 
increased relative to their BeWo-CTB counterpart (paired t test of 3 independent experiments). BeWo-CTB were sampled after 24 h of 
culturing and BeWo-STB were analysed after stimulation with 100 μmol/L forskolin for 48 h. (B) LAT1, LAT2 and 4F2hc transcript levels 
of primary trophoblasts were not significantly increased in STB as compared to the CTB counterpart (paired t test). Primary trophoblasts 
were harvested from 5 individual trophoblast isolations (n = 5). They were lysed for mRNA isolation and quantitative RT-qPCR after 12 h at 
the CTB stage and after 72 h of culturing at the STB stage. (A)/(B) Expression results were normalized to the mean of the reference genes 
YWHAZ, GAPDH and β-actin. Transcript data are presented as fold-change (2−ΔΔCt). Data are shown as mean (+), median (−) and Tukey 
whiskers (1.5-times IQR), α = 0.05, *P < 0.05. (C) Representative immunoblot (left panel) and densitometric analysis of both cell types 
revealed increased LAT1 protein expression after cell differentiation (CTB < STB). Generally higher LAT1 protein expression levels were 
found in the BeWo cell line compared to primary cells (BeWo-CTB/STB > pCTB/STB). The expression of the two LAT2 variants (50 kD; 
30 kD) decreased after trophoblast differentiation in both cell types (primary trophoblasts and BeWo cells). 4F2hc was increased in both 
primary trophoblasts and BeWo-STB as compared to the corresponding CTB stage. Densitometric analysis in the right panel was corrected 
for the β-actin signal
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(10 µmol/L) blocked leucine uptake regardless of the trophoblast dif-
ferentiation stage. In BeWo-STB leucine uptake was inhibited by 87% 
suggesting inhibition of most Na+-independent SLC7 transporters. 
While the dose-response experiments with the less specific inhibitor 
JX009 revealed an EC50 of 3.9 µmol/L for BeWo-CTB and 2.3 µmol/L 
for BeWo-STB, which is comparable with JPH203 (EC50 = 3.1 µmol/L 
for BeWo-CTB and 2.6 µmol/L for BeWo-STB), JG336 was identified 
as the most efficient inhibitor (EC50 = 0.8 µmol/L for BeWo-CTB and 
2.0 µmol/L for BeWo-STB) in both differentiation stages of BeWo cells. 
Compared to the dose-response curve of BCH, JX009 shows com-
parable efficiency but >180-times higher potency (Figure 4C,D). The 
new inhibitors JG336 and JX009 as well as JPH203 reached maximal 
inhibition (first concentration without significant difference to the bot-
tom value) at a concentration of 10 µmol/L, JG336 required 1 µmol/L 
for maximal inhibition in BeWo-CTB. Of note, comparable inhibition 
patterns were also found in the colorectal adenocarcinoma cell line 
HT-29 where lower substrate concentrations (30 µmol/L instead of 
167 µmol/L leucine) lead to lower EC50 values (Figure S3). In sum-
mary, the dose-response analysis of the three inhibitors suggested 
that JG336 inhibits LAT1-specific placental leucine transport similar 
as JPH203, but exhibits an almost 4-times higher efficiency. JX009, 
represents an inhibitor of System L transporters which in trophoblast 
is 180-times more potent than BCH.
3.5 | Transfer of leucine across the placental barrier 
is reduced by inhibitors of System L transporters
The small molecule inhibitors JPH203, JG336 and JX009 were also 
used to assess the relevance of LAT1 and LAT2 in leucine transport 
across the placental barrier using the Transwell® system (Figure 5). 
Leucine transfer experiments were performed in the presence or 
absence of the individual inhibitors with a fixed concentration of 
10 µmol/L applied at the upper compartment. This concentration 
was chosen as it showed in dose-response experiments maximal in-
hibition for all three compounds (see above). Figure 5B shows the ex-
perimental setup and the applied leucine concentrations in the upper 
compartment (corresponding to the maternal side of the placental 
barrier) and the lower chamber (corresponding to the foetal side) 
of the Transwell® system. Gradually diminishing radioactive signal 
3[H]-leucine on the maternal side and increasing radioactivity on the 
foetal side was considered to represent leucine transfer across the 
BeWo monolayer. Treatment with JPH203, JG336 and JX009 at the 
apical (maternal) side caused significant reduction of leucine trans-
fer by 58%, 60% and 55%, respectively. All inhibitors significantly 
decreased leucine transfer from the apical towards the basal com-
partment from 60 minutes onwards. Measurement of intracellular 
3[H]-leucine content in the BeWo monolayer at the end of the trans-
fer experiment (6 hours) indicated significantly decreased intracel-
lular leucine concentrations of 24% for JPH203 and 41% for JG336, 
respectively (Figure 5C). In contrast, JX009 had no effect on the in-
tracellular 3[H]-leucine concentration within the tested time course. 
The higher retention of leucine in JX009 treated cells suggests inhi-
bition of leucine secretion towards the lower foetal compartment.
4  | DISCUSSION
The placenta plays a crucial role in the distribution of essential 
nutrients from the mother to the growing foetus. In this context, 
F I G U R E  3   Similar leucine uptake kinetics in primary and BeWo trophoblast cells. A, In the BeWo cell model, Na+-independent maximal 
uptake capacity (Vmax) for leucine was significantly increased in 3 independent experiments (n = 3). Leucine uptake increased from 
4.96 nmol/mg protein in BeWo-CTBs to 13.41 nmol/mg protein in BeWo-STBs (2 way-ANOVA, α = 0.05; P = 0.018). Leucine uptake for 
BeWo-CTB was performed after 24 h of culturing and for BeWo-STB after stimulation with 100 μmol/L forskolin for 48 h. B, Primary 
trophoblasts isolated from 3 individual control placentae (n = 3) significantly increased their Vmax over 6 min from 1.046 nmol/mg protein in 
pCTB to 2.345 nmol/mg protein in the pSTB stage (2 way-ANOVA, α = 0.05; P < 0.0001). The maximal leucine uptake capacity (Vmax) and 
half-maximal uptake time (Kd) was calculated using a saturation model curve fitting (y = Vmax*X/(Kd + x). The final concentration of leucine 
in all experiments was 167 nmol/mL including 1 µCi/mL 3[H]-L-leucine for detection. Error bars represent standard deviation (SD) of 3 
individual experiments with 6 replicates each
8  |     ZAUGG et Al.
fine-tuned regulatory mechanisms are needed to control the ma-
terno-foetal transfer of essential AA to support the rapidly de-
veloping foetus during pregnancy.43 The current understanding 
of transplacental AA transport is based on the interplay between 
accumulative transporters such as members of the System A family 
and exchangers such as System L family members.44 System A fam-
ily transporters like SNAT1, 2 and 4 are expressed at the MVM and 
accumulate small neutral AA against a concentration gradient in the 
F I G U R E  4   Inhibition of leucine uptake in BeWo cells using small molecule inhibitors with different specificities. Dose-response 
experiments in BeWo-cytotrophoblasts (BeWo-CTB) and forskolin-stimulated BeWo-syncytiotrophoblasts (BeWo-STB) for the established 
LAT1-specific inhibitor JPH203 (A) and for the alternative compound JG336 which carries an additional methoxy group as marked in the 
dashed red box (B). The results showed that both compounds conveyed a significant inhibition (JPH203 = 56%, JG336 = 62%), but also  
suggest that approximately 40% of Na+-independent leucine uptake is LAT1 independent. (C) Application of JX009, an inhibitor of both 
LAT1 and LAT2, resulted in maximal leucine uptake inhibition in BeWo-CTB and BeWo-STB. Compared to the dose-response curve of 
the leucine analog 2-amino-2-norbornane-carboxylic acid (BCH, D), JX009 shows comparable efficiency but >180-times higher potency.  
BCH is a widely accepted inhibitor blocking all System L mediated transport. BCH completely blocked leucine uptake in BeWo-CTB with 
an EC50 of 709 µmol/L and BeWo-STB with an EC50 of 442 µmol/L (D). (A-C) The new inhibitors JG336 and JX009 as well as JPH203 
reached maximal inhibition (first concentration without significant difference to the bottom value) at a concentration of 10 µmol/L, JG336 
required 1 µmol/L for maximal inhibition in BeWo-CTB. BCH reached maximal inhibition at 1 mmol/L in both differentiation stages.  
A-D, All uptake assays were performed in two individual experimental setups (n = 2) for 3 min, under the same conditions in Na+-free Hanks 
buffer with 167.2 µmol/L leucine (1 µCi/mL 3H-L-leucine). Dose-response kinetics were calculated using the nonlinear four-parameter model 
[Y = Bottom + (Top − Bottom)/(1 + 10^((LogEC50-X)*HillSlope))] and ordinary fit with GraphPad Prism software. Best-fit values of the 
including EC50 values are shown to the right of the dose-response curves. Error bars represent standard deviation (SD) of 2 experiments with 
6 replicates
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STB in a Na+-dependent manner.43 The AA accumulated by System 
A transporters can be used as substrates to exchange for essential 
large neutral AA such as leucine by the System L exchangers LAT1 
and LAT2 across the MVM into the STB. The principles of AA up-
take at the MVM are largely characterized, but the contribution of 
single transporters in AA transfer across the BM to the foetus is 
less clear.
In a first step, we investigated the expression and localiza-
tion of LAT1 in the human placenta by immunohistochemistry of 
term placental tissue and by immunoblotting of MVM- and BM-
enriched membrane preparations. We found an exclusive apical 
expression of LAT1 at the MVM confirming previous reports.8,45
So far most mechanistic studies are based on LAT1-
overexpressing cell models like human colon cancer-derived 
HT-29,46 mammary gland derived MCF-7 cells,47 Pichia pastoris42 
or reconstituted 4F2hc-LAT1 proteoliposomes.48 Acquiring further 
detailed knowledge on the complex mechanisms regulating mater-
no-foetal AA transport at the placenta level could be beneficial 
to clarify the relevance of LAT1 and LAT2 in gestational diseases 
such as IUGR and LGA.10 To choose an appropriate physiological 
placental cell model, we compared the BeWo cell line with isolated 
primary human trophoblasts at different stages of differentiation 
by analysing LAT1/LAT2 mRNA and protein expression and leu-
cine uptake. Spontaneous differentiation in primary trophoblasts 
and forskolin-mediated differentiation in BeWo cells provoked 
expressional changes of LAT1, LAT2 and 4F2hc on mRNA and 
protein level (Figure 2). Our results demonstrated that the syncy-
tialization process induced changes in the LAT1:LAT2 ratio as well 
as in 4F2hc expression in both trophoblast models (Figure 2) and 
resulted in an increased leucine uptake under Na+-free conditions 
(Figure 3). These findings imply that differentiation induces a spe-
cialization process both in primary trophoblasts and BeWo cells, 
which results in an increased uptake, transport or transfer capac-
ity as previously shown for the alanine-serine-cysteine transport-
ers and for alpha-aminoisobutyric acid transport.49,50 This concept 
is in line with recent findings that differentiation processes such 
as syncytium formation resulted in an up-regulation of MVM asso-
ciated membrane proteins.16
Based on the validation of expression in the two trophoblast 
cell models (Figure 2) and comparable uptake behaviour (Figure 3), 
the BeWo cell line was chosen to test the effect of different 
SLC7-specific inhibitors. However, to our knowledge LAT1 and LAT2 
localization in MVM or BM of BeWo cells after forskolin-induced dif-
ferentiation has not been reported yet. Thus localization differences 
between primary trophoblasts and BeWo cells cannot be completely 
excluded and therefore the Transwell® data using polarized BeWo 
cells should be interpreted with caution.
The low molecular weight inhibitors JPH203, JG336 and JX009 
were assessed for their capacity to reduce leucine uptake into 
BeWo cells (Figure 4) and leucine transfer across the placental bar-
rier (Figure 5). Due to the varying SLC7 specificity, different inhibi-
tion patterns were expected. JPH203 was previously reported as 
potent, LAT1-specific inhibitor.27-31,46 JX009 had been described 
in the patent literature37 to inhibit LAT1-mediated transport with 
similar efficacy as JPH203, albeit with significantly lower specific-
ity, that is, it is also a potent LAT2 inhibitor. As no other LAT2 inhib-
itors have been described in the literature, JX009 was considered 
the best available tool for the assessment of LAT2-related trans-
port of leucine. JG336 was prepared based on a limited structure 
activity relationships (SAR) study on JPH203 that investigated the 
effects of electron-donating (such as the methoxy group in JG336, 
see dashed red box in Figure 4B), electron-withdrawing and bulky 
substituents on the phenyl moiety at the 2-position of the benzox-
azole ring on transport inhibition. The additional methoxy group 
in JG336 resulted in 3.8-times lower EC50 values in BeWo-CTB 
(Figure 4B) indicating that the inhibition efficiency of JPH203 was 
indeed increased by this modification. Further results of this SAR 
study on JPH203 will be published separately.
Our results demonstrated that all three compounds are highly 
efficient LAT1 inhibitors, but only JX009 conveyed additionally 
LAT2 inhibition. Based on the complete leucine uptake inhibition of 
BeWo cells at the CTB stage, leucine uptake in undifferentiated tro-
phoblasts seems to be highly dependent of LAT1 activity (Figure 4). 
Although we demonstrated in the expression studies (Figure 2) 
that the LAT1:LAT2 ratio in BeWo-STB is higher compared to 
BeWo-CTB, JPH203 reduced leucine uptake in BeWo-STB by only 
60%. This partial inhibition by JPH203 indicates that in BeWo-STB 
leucine uptake is mediated by alternative Na+-independent System 
L or System L-like facilitators such as LAT2, LAT3 or LAT4. JX009 
reduced leucine uptake by 87% regardless of the trophoblast differ-
entiation stage with a low EC50 in the range of JPH203, suggesting 
that JX009 blocked most (if not all) Na+-independent leucine uptake 
transporters. Thus, JX009 is the first characterized System L-specific 
leucine uptake inhibitor in the low µM-range (EC50 < 4 µmol/L; 
Figure 4) for use in placental cell models. To date, the most widely 
used SLC7-specific inhibitor is the non-metabolizable leucine analog 
BCH which has been also tested in this study (Figure 4D) and other 
investigations.51,52 In comparison to JX009 this inhibitor is >100-
times less effective and blocks System L-dependent AA transport 
with 709 µmol/L in BeWo-CTB and 442 µmol/L in BeWo-STB in the 
high µM-range (Figure 4D). Nevertheless, further investigations of 
these small molecule compounds are needed to study viability, ef-
fects on AA metabolism and potential interactions with other trans-
membrane proteins such as System A transporters.
To assess the functional importance of SLC7 transporters in 
leucine transfer across the placental barrier, the effect of the LAT1-
specific inhibitors JPH203 and JG336 as well as the System L inhibi-
tor JX009 was tested in the Transwell® system with polarized BeWo 
cells grown in a tight monolayer (Figure 5). Treatment with JPH203 
during 6 hours reduced leucine transfer across the placental barrier by 
58%. Assuming 100% LAT1 inhibition after treatment with 10 µmol/L 
JPH203 (approximately 5-times the EC50 of JPH203), these results 
suggest that more than half of the leucine transfer across the dif-
ferentiated BeWo monolayer was LAT1-dependent. The 3.8-times 
more efficient inhibitor JG336 (60% reduction), and the less specific 
System L inhibitor JX009 (55% reduction) showed similar inhibition 
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capacities as JPH203. These results demonstrated a predominantly 
LAT1-dependent leucine transfer across the polarized BeWo mono-
layer which mimicks the physiological materno-foetal barrier.39 In 
these transfer studies, we also measured the intracellular leucine 
content at the end of the experiment. In this context, the intracellular 
accumulation of leucine suggests that the efflux activity at the BM; 
that is, the transport towards the foetus, represents the rate-limiting 
process in materno-foetal transfer. In contrast, a reduced intracellu-
lar leucine content predicts leucine transport across the MVM into 
the BeWo monolayer as the rate-limiting step.7 In our experiments 
only the two LAT1-specific inhibitors JPH203 and JG336 caused a 
reduction of the intracellular leucine content (Figure 5C), indicating 
that LAT1-mediated leucine transfer occurs at the apical MVM. In 
contrast, the unchanged intracellular leucine content after JX009 
treatment suggests System L transporter-dependent leucine efflux 
across the BM. This is in agreement with the hypothesis that LAT1 
is the major leucine transporter at the MVM, while other placental 
Na+-independent System L or System L-like facilitated AA transport-
ers such as LAT2, LAT3 or LAT4 mediate leucine efflux across the 
BM (Figure 1) as previously proposed.7,43,53,54 LAT1 and LAT2 local-
ization in BeWo cell before and after differentiation has not been 
demonstrated yet; hence the interpretation of our results is based 
on the assumption that System L-transporter expression in differen-
tiated BeWo is similar to primary trophoblasts and placental tissue. 
Since the three tested inhibitors were applied at the maternal com-
partment, there is a certain membrane and cell layer permeability 
required to allow interactions with the transporters located at the 
BM. Permeability across the trophoblast barrier has not been inves-
tigated, but has been shown in Caco-2 cells for JPH203.40 Recently 
Lewis et al demonstrated in a mathematical modelling approach of 
placental AA efflux based on placental perfusion data, that LAT2 al-
lows the transport of a substrate across the BM without transport of 
another molecule in the other direction as normally expected from a 
classical exchanger.55
F I G U R E  5   Relevance of LAT1 and System L inhibition in leucine transfer across the placental barrier in vitro. A, Leucine transfer across 
a tight BeWo monolayer was measured from the apical (ie upper compartment) towards the basal (ie lower compartment) side during 6 h 
using the Transwell® system. Leucine transfer was significantly reduced by the System L inhibitor JX009 (orange) and the LAT1-specific 
inhibitors JPH203 (red) and JG336 (green) compared to the DMSO-control (black) already after 1 h. Equal concentrations (10 µmol/L) of 
each inhibitor and DMSO as vehicle control were applied in three experiments with two replicates per condition. B, Illustration of the 
experimental setup. All leucine transfer assays were performed against a counter-directed gradient of 137 µmol/L (30 → 167 µmol/L) 
leucine, in the presence of 300 µmol/L glutamine (Gln) in both compartments. The leucine in the upper compartment was spiked with 
1 µCi/mL 3H-L-leucine for transfer quantification. C, The intracellular leucine content was measured after washing the cell layers with 
DPBS at the end of the experiment (after 6 h). A significant reduction of intracellular leucine contents was detected for the LAT1-specific 
inhibitors JPH203 (P = 0.020) and JG336 (P = 0.0001), but not for the System L inhibitor JX009- (P = 0.215). The detected intracellular 
leucine retention caused through LAT1 and LAT2 inhibition by JX009 suggests a System L-dependent leucine efflux across the BM as rate-
limiting step. Statistical analyses were performed using a parametric one-way ANOVA analysis (α = 0.05)
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The selective expression and overexpression in various cancer 
types with poor survival expectancy20,56-60 made LAT1 an inter-
esting pharmaceutical target.27 This study demonstrates that the 
choriocarcinoma cell line BeWo could serve as useful model sys-
tem to test putative LAT1 inhibitors and characterize their effect at 
an active AA transporting and physiologically relevant cell barrier. 
It was shown that high and asymmetric expression of SLC7 family 
members makes the placental leucine uptake sensitive to LAT1- and 
LAT2 inhibition.8,41 Furthermore, the application of compounds 
like the LAT1-specific inhibitor JPH203 or the less specific SLC7-
transporter inhibitor JX009, allows for distinguishing the contribu-
tion of single leucine transporters across the placental barrier. The 
short-term treatment with small molecule inhibitors also reduces 
the risk of affecting trophoblast fusion and differentiation which 
could occur after long-term gene silencing or constitutive knock-
out.16 If further efforts are made to identify new lead structures or 
to further develop existing inhibitors targeting System L-like trans-
porters such as the AA facilitators LAT3 and LAT4, these new com-
pounds could be valuable tools for assessing the relevance of single 
transporter in materno-foetal AA transfer.
In summary, the combined application of the LAT1-specific in-
hibitor JPH203 and the System L inhibitor JX009 in Transwell® 
studies helped to identify LAT1 as major leucine transporter play-
ing an important role in the materno-foetal supply of essential AA 
at the MVM. In this context, the present study demonstrates the 
usefulness of applying small-compound inhibitors bearing different 
specificities. A better understanding of the SLC7 transporter-medi-
ated supply of AA and its impact on mTORC1-mediated placental 
function in pregnancy diseases including IUGR and gestational dia-
betes mellitus could be a first step towards the optimization of foetal 
growth and its effect on foetal programming in the future.61
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